Results 111 to 120 of about 17,683 (178)

Evaluating the risk of recurrence in neovascular age-related macular degeneration using OCT-angiography at the time of treatment exit. [PDF]

Br J Ophthalmol
Jaggi D, Marugg S, Berger LE, Munk MR, Zinkernagel MS, Heussen FM.   +5 more
europepmc   +1 more source

Targeted Fluorescence Imaging of Bevacizumab-800CW in Patients with Neovascular Age-Related Macular Degeneration. [PDF]

J Nucl Med
Schmidt I, Volkmer P, Müskens RPHM, van der Waaij AM, van Dam GM, Huiskamp EA, Nagengast WB.   +6 more
europepmc   +1 more source

Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg. [PDF]

J Ophthalmol
Veritti D, Misciagna M, Teatino C, Pontoni C, Blasutig M, Kuftic M, Pece S, Morsanutto A, Pece A, Lanzetta P.   +9 more
europepmc   +1 more source

Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care. [PDF]

Ophthalmol Ther
Gil-Rojas Y, Nicholson L, Eymere S, Cox O, Bagijn M.   +4 more
europepmc   +1 more source

Long-Term Follow-Up of Faricimab Intravitreal Injections in Naïve Neovascular Age-Related Macular Degeneration.

Ophthalmic Res
Belloni Baroni L, Toto L, Formenti F, Passamonti M, Quarta A, Ruggeri ML, Aloia R, Di Nicola M, Mastropasqua R.   +8 more
europepmc   +1 more source

Outer Retinal Hyperreflective Foci as a Predictor of Hyperreflective Material Boundary Remodeling and Visual Outcomes in Neovascular Age-Related Macular Degeneration. [PDF]

Medicina (Kaunas)
Jovanović M, Milošević J, Carrasco Guijarro M, Jovanović S, Todorović D, Petrović N, Paunović S, Janićijević K, Živković MLJ.   +8 more
europepmc   +1 more source

Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration. [PDF]

Graefes Arch Clin Exp Ophthalmol
Hashiya N, Maruko I, Maruko R, Kakehashi M, Kawahara K, Nishihara S, Iida T.   +6 more
europepmc   +1 more source

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. [PDF]

Ophthalmol Ther
Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebneter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR, Swiss Retina Research Network.   +21 more
europepmc   +1 more source

Association between screening duration and treatment outcomes in the clinical trials of ranibizumab and aflibercept for neovascular age-related macular degeneration. [PDF]

Sci Rep
Kim HM, Woo SJ.
europepmc   +1 more source

Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society. [PDF]

Invest Ophthalmol Vis Sci
Akada M, Ideyama M, Kido A, Miyata M, Ueda-Arakawa N, Tamura H, Ooto S, Miyake M, Tsujikawa A, Hata M.   +9 more
europepmc   +1 more source